Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13226303 | 1.00 | CCR2 (0.57) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13645857 | 0.93 | CCR2 (0.54) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13646031 | 0.93 | CCR2 (0.54) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13650495 | 0.88 | CCR2 (0.58) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL17385593 | 0.84 | CCR2 (0.55) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13646158 | 0.83 | CCR2 (0.63) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL5549680 | 0.83 | CCR2 (0.63) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13645862 | 0.83 | CCR2 (0.63) | CCR2 | |
| SCHEMBL13646037 | 0.83 | CCR2 (0.51) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13646060 | 0.83 | CCR2 (0.63) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7410961-B2 | 2,6-disubstituted piperiddines as modulators | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1501507-B1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20070179158-A1 | 2,6-Disubstituted piperiddines as modulators | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179158-A1 | 2,6-Disubstituted piperiddines as modulators | CCR2, CCR7, CCR9 | CCR2 1/4885CCR1 6/4885TMEM97 819/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | CCR2 3/4885CCR1 4/4885TMEM97 1640/4885 |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | CCR2 3/4885CCR1 1/4885TMEM97 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.